Even in a best-case scenario involving: constant ("smart") drug release from the nanoparticles; a homogenous tumor of one cell type, which is drug-sensitive and does not develop resistance; targeted nanoparticle delivery, with resulting low host tissue toxicity; and for model parameters calibrated to ensure sufficient drug or nanoparticle blood concentration to rapidly kill all cells in vitro; our analysis shows that fundamental transport limitations are severe and that drug levels inside the tumor are far less than in vitro, leaving large parts of the tumor with inadequate drug concentration. A comparison of cell death rates predicted by our simulations reveals that the in vivo rate of tumor shrinkage is several orders of magnitude less than in vitro for equal chemotherapeutic carrier concentrations in the blood serum and in vitro, and after some shrinkage the tumor may achieve a new mass equilibrium far above detectable levels. We also demonstrate that adjuvant anti-angiogenic therapy "normalizing" the vasculature may ameliorate transport limitations, although leading to unwanted tumor fragmentation. Finally, our results suggest that small nanoparticles equipped with active transport mechanisms (e.g., chemotaxis) would overcome the predicted limitations and result in improved tumor response.
Introduction
There has been intensive research during the past few decades in the use of nano-scale particles (100 nm or less) in medicine, especially for delivering chemotherapeutic agents to cancer cells. Nanoscale devices carrying chemotherapeutic drugs could extravasate from blood vessels and even diffuse through the tissue and enter tumor cells. Drug delivery through nanoparticles presents significant potential advantages over traditional delivery via bolus injection. Tumor vessels are dilated, saccular, and hyper-fenestrated, often containing cancer cells within the vessel endothelial lining. Hobbs et al. (1998) found that the pore sizes in one human and five murine tumors range from 380-780 nm, significantly higher than in normal tissue. Taking advantage of the pore size differential between tumor and normal vasculature, long-circulating nanoparticles could be sized so as to extravasate only from tumor vasculature (Kreuter and Hartmann, 1983; Beck et al., 1993) . Such targeted delivery could greatly reduce drug tissue toxicity and make it possible to choose moderate, constant doses leading to long time periods of cell exposure to the drug over pulsed maximum tolerated dosing.
Once the particles have successfully been deposited in the tumor, they would kill cancer cells through two possible mechanisms. For nanoparticles on the order of 100 nm, the extravasated particles, being too bulky to diffuse, would release their drug via desorption of surface-bound drug, diffusion through the polymer wall, and nanoparticle erosion. In this way they would function as stationary sources of drug within the tumor. In vitro release experiments have shown that a near constant release can be maintained for months (Feng and Chien, 2003) . Smaller particles capable of diffusion throughout the tumor interstitium could also be employed: 1-10 nm particles have been demonstrated capable of targeting cancer cells that are folate receptor-positive and delivering a therapeutic payload, such as methotrexate, specifically to these cells (NIH Publication No. 04-5489, 2004) . Combining the strategies of tumor-specific extravasation and cell-specific constant dose targeting ("smart" delivery) has the potential to greatly increase the efficacy of the drug while simultaneously reducing host tissue toxicity. Experiments with rats and mice have shown that anticancer drug delivered via nanoparticles can result in increased tumor cell kill as well as decreased toxicity when compared with free drug administration (Kreuter, 1994) . Wang et al. (1999) compared in two-dimensional computer simulations controlled release from polymers and systemic administration, and found that in contrast with bolus injection, polymer-based delivery imparted a longer exposure time, a higher mean concentration, and a reduced systemic toxicity.
However nanoparticle chemotherapy strategies (and traditional chemotherapy (McDougall et al., 2002) ) face delivery limitations due to poor transport. The tumor vasculature is notorious for its irregularity (Haroon, 1999; Jain, 1990 Jain, , 2001b . Tumor vasculature does not follow the normal organizational pattern in which artery connects to arteriole to capillary to postcapillary venule to venule to vein. Instead, a tumor venule may connect to another venule via capillaries or postcapillary venules. The organization may also be spatially and temporally heterogenous. The hyperpermeable vasculature (Jain, 1987) together with a lack of a functional lymphatic system results in increased fluid pressure within the tumor (Jain, 2001b) . In addition to interstitial fluid pressure, a tumor has a separate mechanical pressure associated with cellular proliferation (Padera et al., 2004) . Padera et al. (2004) found that this mechanical stress plays a key role in the collapse of tumor vessels and further restriction of the blood supply see also the recent work by Sarntinoranont et al. (2003) . The blood flow in tumors grown in transparent windows has been investigated and found to be intermittent, periodically abating and reversing (Jain, 1988 (Jain, , 1990 . The extravasation of a macromolecule or a nanoparticle from a blood vessel depends primarily upon convection. As a result of the abnormal features of tumor vasculature, the convective transport of molecules and particles is compromised.
Once a molecule or a particle has extravasated from a blood vessel, it must diffuse across the interstitium. The time required for a molecule to diffuse across tumoral tissue may be of the order of days for a 1 mm distance, and months for a 1 cm distance (Jain, 1990 (Jain, , 2001b . As demonstrated by Jain (1990) , in a hypothetical tumor uniformly perfused with vessels about 200 µm apart, with sufficiently high interstitial pressure to stop fluid extravasation in the center, and with some collapsed vessels due to cell proliferation, it may take from days to months for a macromolecule to diffuse into the center. Thus, considering only convection from the blood vessels and diffusion across the tumor interstitium, a molecule faces impediments to its final delivery. This is ignoring further problems such as multi-drug resistance in the case of anticancer drugs, and non-specific and specific binding.
It has been proposed that tumor vasculature could be "normalized" via antiangiogenic therapy (Jain, 2001a) . Pruning immature and inefficient blood vessels may lead to a more normal vasculature of vessels reduced in diameter, density, and permeability, which may in turn lead to lower interstitial pressure or cell-cell mechanical pressure (Jain, 2001a; Padera et al., 2004) . In the first case, since the convection of molecules or particles across a blood vessel wall is proportional to the difference in blood vessel pressure and tumor interstitial pressure, a lowering of the latter should increase the amount of drug or particle delivered into a tumor. In the second case, collapsed tumor vasculature due to mechanical stress may be restored thereby increasing the amount of functional vessels inside the tumor.
In this article, we investigate these issues using multidimensional computer simulations. The tumor simulator is based on a reaction-diffusion model of tumor progression (Chaplain, 1996) and angiogenesis (Anderson and Chaplain, 1998) solved using a novel finite-element/levelset method (Zheng et al., 2004) in two spatial dimensions coupled to an unstructured adaptive mesh technology (Cristini et al., 2001 ) that allows efficient and accurate solution of the model equations. This implementation allows for the first time the simulation of tumoral lesions through the stages of diffusion-limited dormancy, localized necrosis, vascularization and rapid growth, and tissue invasion in multiple spatial dimensions. We here incorporate a simple model of nanoparticle delivery by convection from the bloodstream, and the release, diffusion and action of the anticancer drug contained therein. Very small, diffusing nanoparticles are also considered. The coupling of this chemotherapy model to the tumor simulator previously developed by Zheng et al. (2004) enables us for the first time to directly simulate and quantify in silico the spatial dependence of tumoral tissue regression in the presence of anticancer drug on the heterogeneity of the tumor and vessel morphology, and on the internal mechanical pressure and drug concentration gradients, and thus to explore the benefits and limitations of nanoparticle chemotherapy.
Multidimensional Computer Model of Tumor Progression and Nanoparticle Chemotherapy

Reaction-diffusion model of tumoral lesion progression and angiogenesis
Here we briefly describe the model incorporated in the computer simulator presented by Zheng et al. (2004) . Even a small, 1 mm tumor spheroid already contains roughly one million cells, therefore a continuum model is used to describe the tumor mass. Consider a tumoral lesion consisting of a region of viable tumor tissue V and of necrotic tissue N embedded in an extra-tumoral "healthy" tissue domain H (Figure 1 ). In the schematic, ongoing angiogenesis is depicted by the capillary sprouts propagating towards the tumor. The transport of molecules or particles across the microvascular wall is primarily due to convection, although diffusion and transcytosis also play a role (Jain, 1990 (Jain, , 2001b . Convection is dependent upon the difference of the vascular and interstitial hydrostatic pressures, the difference of the vascular and interstitial osmotic pressures, and the nutrient concentration in the bloodstream, while diffusion is proportional to the difference of the vascular and interstitial concentrations. Here, for simplicity we focus on the effects of pressure and nutrient concentration gradients across the microvascular wall, neglecting osmotic pressure and transcytosis, along the lines followed by Byrne and Chaplain (1995) , Chaplain (1996) , Cristini et al. (2003) , and Zheng et al. (2004) . We model the net local rate of nutrient delivery from the neo-vasculature and uptake by the tumor cells as
where n is the local nutrient concentration, n v is the nutrient concentration in the vasculature (herein, nutrient and chemotherapeutic carrier concentrations will be normalized with n v ), p is the pressure in the tumor, p v is the pressure in the vasculature, ν 1 is the transfer coefficient from the vasculature, η is the rate of nutrient uptake within tumor cells, and δ is the indicator function of vasculature (1 where it exists, 0 otherwise). The notation (᭹) + means max{᭹, 0} and is used for the blood-to-tumor pressure difference term because if it approaches zero the blood vessel will collapse, allowing nothing to pass either way (Padera et al., 2004) . It must be noted that this model is single phase, the "tumor" phase encompassing tumor cell matter, interstitial fluid, and extracellular matrix, and therefore no distinction between interstitial fluid hydrostatic pressure and mechanical pressure due to cell-cell interactions is made. These pressures can be different within the tumor tissue, and can play distinct roles in the rate of exchange with the blood stream (Jain, 1990 (Jain, , 2001b Padera et al., 2004) . Thus in our model only the overall effect is described.
As the time scale of nutrient diffusion is on the order of minutes, and that of tumor cell proliferation is on the order of days (Byrne and Chaplain, 1995) , nutrient diffusion through the tumor interstitium is modeled by the quasisteady state equation
where D is the diffusion coefficient, here assumed constant. As described in Section 2.2, an analogous model is used here for the transport of chemotherapeutic agents. We next describe the effect of nutrient on cell proliferation. A typical, cycling eukaryotic cell cycles at a rate λ M of about one inverse day. At any given time there is a fraction of cells that have passed the G 1 restriction point and are therefore cycling (Cooper, 2000) . Growth factors and nutrients such as vitamins A and D, folic acid, glucose, and oxygen regulate the entry of a cell into its cycle (Bohnsack, 2004) . We assume that the tumor tissue is saturated with growth factors, and that nutrient availability limits cell proliferation, and therefore we model the fraction of cycling cells by n/n v , where n will not exceed n v . Under the additional model assumption that cell mass density is uniform in the tumor (Chaplain, 1996) , the local specific mass growth rate is the divergence of the tumor cell's velocity field u and is related to proliferation in
where λ D is a death term by apoptosis, to be described shortly, that depends on the local levels of chemotherapeutic agent (e.g., nanoparticles, drug molecules). We assume there is no proliferation in healthy tissue H , and that in necrotic regions N the divergence of the cell velocity field is a negative constant -λ N that describes the disintegration of cell mass and the radial effusion of fluid away from the necrotic regions (Chaplain, 1996) . Necrotic regions are defined to be regions in which the nutrient falls below some specified minimum (Zheng et al., 2004) . In equation (3), the spatially dependent local nutrient concentration n is calculated by solving equations (2) with (1).
Treating the tumor cells and extracellular matrix as comprising porous media with hydraulic conductivity µ, we model the velocity and cellular pressure by Darcy-Stokes' law (Truskey et al., 2004) which, neglecting viscous terms, describes how the cell motion induced by proliferation generates an heterogeneous pressure field within the tumoral lesion:
This pressure in turn affects delivery of nutrients (and chemotherapeutic agents) according to equation (1). Equation (3) and the above equation are solved for the local velocity of cell motion from proliferation and the corresponding pressure.
Nutrient (and chemotherapeutic agent) consumption by the tumor cells implies that nutrient (and the drug) is not able to diffuse adequately to feed (kill) all of the tumor cells. In the case of nutrient transport, cells that are too far away from blood vessels therefore die, forming necrotic regions. Without a blood supply, the tumoral lesion cannot grow beyond a diffusion-limited size of a few millimeters. Cells undergoing necrosis are hypothesized (Chaplain, 1996) to send out a tumor angiogenic factor (TAF) that triggers the formation of the neo-vasculature. To model this the tumor simulator (Zheng et al., 2004) incorporates an angiogenesis component based upon the work of Anderson and Chaplain (1998) . This is essentially a reinforced random walk of new blood vessels drawn into the tumor via chemotaxis and other mechanisms. Once the blood vessels have penetrated the tumoral lesion, they feed it and allow it to grow rapidly and to invade proximate tissue. This neo-vasculature is also responsible for the delivery of chemotherapeutic agents to the lesion.
Model of nanoparticle chemotherapy
We present two models for nanoparticle chemotherapy that isolate features of extravasation from the neovasculature and diffusion into the tumoral tissue. The first model best describes nanoparticles of size 1-10 nm (NIH, 2004) (and also drug molecules if traditional intravenous drip administration is considered instead of nanoparticles); the second model applies to larger, 100 nm particles (Kreuter, 1994) .
In the former case we assume that the local concentration s of the chemotherapeutic carrier remains constant equal to s v in the blood serum during the course of therapy, and we study spatial and temporal tissue and vessel heterogeneities limiting carrier extravasation and diffusion. Ideally, 1-10 nm particles convect from the vasculature, diffuse through the tumor interstitium, and enter cancer cells just as do nutrient or drug molecules, and so the transport of the rescaled variable s/n v is governed by the analogues of equations (1) and (2), with (1) modified to read:
In the latter case, heterogeneities in extravasation still apply, as discussed above. However, to focus on limitations to diffusion of the drug through the interstitium after being released by the nanoparticles, here we assume that nanoparticles are administered once, extravasate uniformly and thoroughly into the tumor tissue on a short timescale, and remain near the neo-vasculature (nanoparticles of 100 nm are too bulky to diffuse once extravasated) releasing their load of drug molecules that diffuse into the tumoral tissue. Thus we consider the best possible outcome of extravasation, such as the scenario of outcome of adjuvant anti-angiogenic therapy used to normalize the vasculature. Models and quantitative experimental results of drug release from nanoparticles are discussed by Siepmann and Gopferich (2001) , Kreuter (1994) , and are reviewed by Feng and Chien (2003) and by Frieboes et al. (2004a) . Frequently, an initial rapid release occurs due to drug adsorbed on the surface of the particle, followed by a more sustained release of incorporated drug (Soppimath and Aminabhavi, 2001; Kreuter, 1994; Illum et al., 1986) . This biphasic release from a nanoparticle can be modeled by C t = 1 − (Ae −αt + Be −βt ), where C t is the fraction of released drug at time t, A and α are parameters corresponding to the rapidly released portion, and B and β are parameters corresponding to the slowly released portion. Since α > β, as time progresses the term corresponding to the rapid release becomes negligible, leading to C t ≈ 1 − Be −βt ≈ (1 − B) + Bβt, or constant release at a rate of Bβ. Therefore, we assume that once extravasated the nanoparticles provide a constant source of drug along the vasculature. Drug diffusion is thus described using the analogues of equations (2) and (1), where s is now the drug molecule local concentration, and in equation (1) the transfer/uptake rate is simply
where ν 2 is a constant flux of drug molecules into the tissue related to the rate of release Bβ. We now consider the effect of the chemotherapy carrier on cell proliferation. It is well established that, for a fixed time of exposure to an anticancer drug, the logarithm of the surviving fraction of cultured cells is linear with respect to dose (Friedman et al., 1979; Skipper et al., 1979) . Moreover, cytotoxicity is a function of the dose integral with respect to time (Martin et al., 1989) . However, this is true only for the proportion of cycling cells n/n v , as many anticancer agents are proliferation or even cell-cycle-phase specific (Schwartz, 1979) . Thus, letting N be a cell population uniformly exposed (e.g., in vitro) to a carrier concentration s and to a nutrient concentration n, N 0 be the initial cell population, and t be the time of exposure, we have
where λ A is the apoptosis rate reflecting the effectiveness of the drug. In our space-dependent model, the cell death term in equation (3) becomes then
where s is the local concentration of the chemotherapeutic carrier.
In the following simulations we consider a best-case scenario in which there is only one clone of tumor cells, which is drug-sensitive and which does not develop resistance. Additionally, we assume that nanoparticles are delivered only to tumor tissue and therefore result in no host tissue toxicity. Finally, we assume that there are no transport limitations other than convection and diffusion (e.g., non-specific binding). Zheng et al. (2004) provide a detailed and rigorous determination of the microphysical model parameters focusing on the case of glioblastoma multiforme, a malignant brain tumor characterized by rapid growth and infiltration (Maher et al., 2001 ). Here, we follow their approach. From our experiments (Frieboes et al., 2004b) on the growth of glioblastoma cell lines as multicellular millimeter-size spheroids in vitro, a typical mitosis rate λ M ≈ 0.3 day −1 was observed. Since spheroids in culture reach a constant size, the rate of volume loss in the necrotic core is comparable to the rate of volume gain from mitosis, hence the choice λ N = 0.075 day −1 (Zheng et al., 2004) . For nutrient (and chemotherapy agent) delivery, the transfer coefficient of the vasculature was set, after some experimentation, to a value ν 1 = 0.025 min −1 (Zheng et al., 2004) . By considering a characteristic value for the diffusion constant D = 10 −5 cm 2 /s and a consumption rate η = 1 min −1 (Zheng et al., 2004) , we obtain a characteristic diffusion length L = (D/η) 1/2 ≈ 250 µm. We select the cell kill rate to be the same as the mitosis rate: λ A ≈ 0.3 day −1 . For the first model, we need to determine the chemotherapy agent (drug molecules or small nanoparticles) concentration in the bloodstream s v to be used in equation (4a). While this concentration is not synonymous with that of actual drug, the exact relationship being dependent upon the loading properties of the particles used, we make no attempt to model this distinction, as it will not affect qualitatively the results presented here. In the present work, this parameter cannot be directly related to actual carrier concentration levels in the blood serum, as this would also require direct measurement of λ A in equation (5). To calibrate this parameter, we imagine instead an in vitro experiment prior to in vivo chemotherapy, in which the concentration of chemotherapy agent (drug molecules or nanoparticles) is chosen to be sufficient to kill cells under high nutrient conditions (and therefore all cycling: n = n v ) on a timescale on the order of hours. Selecting a tumor half-life of 8 hours we calculate the required chemotherapeutic agent concentration in the blood serum from equation (5) with N /N 0 = 1/2 to yield s v /n v = 7. The corresponding in vitro death rate λ D = 0.3 · 7 = 2.1 day −1 (from equation (6)) will form a baseline against which to measure the effectiveness of both simulated therapy models in vivo.
Choice of parameters
For the second model, in which we assume that a certain quantity of nanoparticles has been uniformly extravasated into the tumor, we do not need to consider the concentration in the bloodstream. Instead, we need to determine the constant flux ν 2 according to equation (4b). To calculate this parameter from experimental data on release from a nanoparticle, we would also need to know the tissue concentration of extravasated nanoparticles, and the amount of drug in each nanoparticle. Instead, for simplicity here we allow for a flux that will be effective in killing tumor cells on a typical time scale of drug release from a nanoparticle (Bβ) −1 = O (100 days) (Feng and Chien, 2003) . After some experimentation, this can be achieved using a value ν 2 = 0.015 min −1 .
Simulations of Nanoparticle Chemotherapy
To investigate numerically transport limitations to drug delivery using nanoparticles, and the tumor response to the drug, we focus on the case of glioblastoma multiforme, which is an aggressive brain tumor that may present as the last stage of astrocytoma progression, or de novo. It is extremely recalcitrant to all forms of therapy, whether surgical, genetic, chemical, or radiological. This is in part due to the high motility of glial cells, rendering the tumor highly diffuse on the periphery (Maher et al., 2001) . We first present a simulation of the growth of a highly perfused lesion within this glioma. Then we present simulations of chemotherapy under the assumptions described above. We consider two ends of a spectrum-model one which best describes very small nanoparticles (or drug molecules) that are assumed to convect from the bloodstream and diffuse through the tumoral tissue, and model two that applies to large nanoparticles that are assumed to remain at their point of extravasation from the vasculature and function as a constant source of drug along the vessels. The drug itself diffuses through the tumoral tissue. This latter simulation is constructed to highlight difficulties in diffusion alone. We show that transport limitations impede the efficacy of the drug in causing tumor regression. We also indicate the possible benefits of improving drug delivery due to increased nanoparticle extravasation via the use of adjuvant anti-angiogenic drugs to "normalize" tumor vasculature (Jain, 2001; Padera et al., 2004) .
Fig. 2. Morphology evolution from a simulation of glioblastoma multiforme. At t = 100, a necrotic region has formed (thin black outline) because of limited nutrient availability; at t = 240 and 300, a growth instability leads to formation of fragments of tumoral tissue; also, penetration of capillary sprouts into the tumoral tissue occurs
; by t = 400, the tumoral lesion grows and co-opts the vasculature; at t = 1000, the tumor stabilizes. The two contour plots "P" and "RN" show the pressure p/ p v and nutrient level n/n v corresponding to the last frame at t = 1000. In all following simulations, legends span same value ranges for comparison. Note that pressure in the undisturbed healthy tissue is set to zero. Note also that the tumor acts as a "sink" of nutrient and oxygen. Figure 2 presents five snapshots of an evolving tumoral lesion morphology throughout its entire simulated growth, along with the scaled pressure p/ p v and the nutrient concentration n/n v profiles in the tissue for the last snapshot at time t = 1000 (note that within the tumoral tissue, this dimensionless nutrient concentration also denotes the
Simulation of the growth of a highly perfused lesion of glioblastoma multiforme cells
Fig. 3. Tumor mass vs. time. The mass corresponds to a cell density of 1 and is made dimensionless using L 2 . The time unit is 1/λ M ≈ 3.3 days. A: Tumor growth without chemotherapy; B: Chemotherapy simulation involving small, diffusing chemotherapy carriers (model one); C: Chemotherapy simulation involving large, non diffusing nanoparticles but in conjunction with adjuvant anti-angiogenic therapy (model two); D, E: Simulations corresponding to B and C but assuming higher blood vessel mobility.
fraction of cycling cells). Time has been nondimensionalized by the mitosis time λ −1 M ≈ 3.3 days. Likewise, distance has been non-dimensionalized by the characteristic nutrient diffusion length L ≈ 250 µm (see Section 2.3). The solid thick contour denotes the interface between the tumoral and nontumoral tissues, the solid thin contour the boundary of necrotic areas within the tumoral tissue. The newly formed capillaries are also shown during angiogenesis. Some capillaries have formed loops through anastomosis and conduct blood, whereas some don't. The dotted contours describe the density of "free" endothelial cells migrating chemotactically (Anderson and Chaplain, 1998 ) from six, pre-selected locations occupied by vessels (not shown) in the outer tissue, towards the source of tumor angiogenic factors (TAF) in the necrotic areas. This in silico idealized model enables us to describe tumor induced angiogenesis and perfusion of the growing lesion. The upper solid line labeled "A" in Figure 3 shows the 2-D tumor mass versus time (here, tissue density is assumed to be constant and equal to 1 (Zheng et al., 2004) , and thus the mass is non-dimensionalized with L 2 ). The first frame in Figure 2 shows the tumor at time t = 100. Due to the heterogeneity of nutrient distribution following diffusion from the nonuniform preexisting vessels and uptake by the cells, the tumoral lesion has formed a necrotic region (solid thin outline) where nutrient concentration is very low. At this point the 2-D lesion has reached a diffusion-limited equilibrium where the rate of proliferation in the outer layer balances the rate of cell mass destruction in the necrotic region (Byrne and Chaplain, 1997) . TAF (not shown) emanates from the necrotic region and spreads radially outward, reaching the pre-existing vessels and triggering angiogenesis. During angiogenesis, the tumor cells tend to co-opt the complexly shaped neo-vasculature in order to maximize nutrient uptake. Note that penetration of the lesion by the new capillary sprouts has begun by time t = 300. By time t = 400 the tumoral lesion has assumed the contours of the vasculature.
In addition, as the tumor progresses, it experiences a morphology instability (Byrne and Chaplain, 1997 ) that is already visible by time t = 240. This instability is caused by the heterogeneous nutrient distribution that leads to nonuniform cell proliferation and growth of cell mass. This nonuniform growth (also enhanced by necrosis and its associated mass loss) is modulated by cell-cell adhesive forces (also modeled in the simulator developed by Zheng et al. (2004) and used here). For the parameters used here, cell adhesion is insufficient to maintain the proliferating cells together thus allowing cell clusters to grow and separate from one another. The lesion almost breaks up into fragments at time t = 300. In our in vitro experiments (Frieboes et al., 2004b ) on a human glioblastoma multiforme cell line, spheroids were cultured and it was observed that at high serum and nutrient concentrations, the spheroids first grow to a diffusion-limited millimeter size, and then become morphologically unstable, suggesting that heterogeneous proliferation is not balanced by the low cell adhesion (possibly due to absent or mutated tumor suppressor genes such as E-Cadherins), and assume dimpled shapes as in our simulation. These sub-spheroid structures were often observed to eventually break off the main spheroid and this process to repeat itself. Diffusional instability is well known in materials science, and has been studied in detail by Cristini et al. (2003) and by Zheng et al. (2004) in the context of tumor growth. It is believed to be an important component of the infiltrative phenotype of brain tumors and other tumors. As we will show in the following, also non-homogeneous drug distribution within the tumoral tissue will cause nonuniform cell proliferation and thus will cause a similar instability of the tumoral lesion morphology during therapy leading in some cases to tumor fragmentation.
The last frame in Figure 2 shows a late stage of evolution at time t = 1000 (corresponding to a growth timescale of 1000λ −1 M ≈ 9 years), when the tumoral lesion has completed its progression and has achieved a new equilibrium between cell proliferation and necrotic death, as is evidenced by the reduced slope in curve "A" in Figure 3 . At this stage, the lesion spans a linear dimension of roughly 30L = 0.75 cm. These data are in satisfactory agreement with the observed progression from astrocytoma to secondary glioblastoma (Maher et al., 2001) . Note, in Figure 2 , the high pressure developed within the 2-D lesion due to high cell proliferation. The corresponding nutrient concentration profile is lowest inside the lesion, as the high cellularity therein acts as a formidable sink of nutrients. An inspection of the tumor morphology reveals distributed areas of viable tumor tissue surrounding the new capillaries. The thickness of these viable regions scales with the nutrient diffusion length L. Consequently, scattered necrotic areas form beyond a distance L from the vessels. This predicted morphology is in agreement with biopsies of gliomas (Burger and Kleihues, 1989) . As further support to the realism of our simulations, it is useful to estimate the cellularity in the simulated lesion. Assuming a linear cell dimension O(10 µm), we can estimate the ratio of tumor and endothelial cell numbers. From Figure 3 at time t = 1000 the dimensionless tumor mass is 530; the total dimensionless capillary length is calculated in our simulation to be 2027. From these numbers, the total numbers of cells can be estimated. Taking their ratio and scaling from two to three dimensions using an exponent 3/2, yields that the predicted ratio of tumor-toendothelial numbers of cells is O(100), in good agreement with experimental observations (Bussolino et al., 2003) .
Simulations of nanoparticle chemotherapy
The simulation shown in Figure 4 (model one) illustrates features of convection/extravasation and diffusion of a number of different delivery carriers, such as free drug molecules, liposomes, current nanoparticles (only convection/extravasation), and nanoparticles in development, which are small enough to diffuse after they are extravasated. Therefore we consider nanoparticles at a constant blood serum concentration s v /n v = 7 (see Section 2.3) being convected continuously through the blood vessels, extravasating and diffusing subject to the analogues to equations (1) and (2) for the local nanoparticle concentration s (or other chemotherapy carrier). Equation (1) is modified into (4a) as described in Section 2.2.
As shown in Figure 2 , at time t = 1000 right before therapy is started, an inspection of the morphology of the tumoral tissue reveals a non-uniform distribution of newly formed blood vessels around which tumor cells are proliferating. Scattered islands of necrotic cells are also visible. In addition the pressure distribution due to cellular proliferation is highly non-uniform, being highest in the center of the lesion. It is clear that the local level of chemotherapy agent after extravasation (and the tumor response) will be the result of the competition of pressure opposing convection and density of vessels that favors delivery. As the morphologies in Figure 4 at times t = 1028 (shortly after therapy has started) and t = 1200 reveal, the delivery is indeed highly non-uniform. In particular, it is immediately apparent that the highest delivery of chemotherapy agent occurs in the central region of the 2-D lesion. This is a result of the competition of a high pressure and a high density of vessels observed in Figure 2 . We have run a number of simulations under similar conditions that reveal that the outcome of this competition is not always in favor of increased extravasation. As a consequence of the non-uniform delivery of the chemotherapy agent, Figure 4 reveals that tumor regression is likewise non-uniform, being maximum around areas of maximum drug extravasation. Note also that tumor cell regression causes a local decrease of pressure, which, in turn, causes a local increase in drug delivery (Padera et al., 2004) . After the chemotherapy agent is extravasated, penetration into the tumoral tissue is the result of the competition of diffusion and uptake by the cells. This strongly limits the area around the vessels that is permeated by the diffusing chemotherapy agent.
Note that here we are describing numerically a 2-D slice of perfused tumoral tissue, for example within the viable region of tissue belonging to a large tumor. Our simulations do not aim to describe a whole tumor, which is typically characterized by an outer layer of viable (and scattered necrotic) cells, enclosing a large core of necrotic cells, mixed often with immune system cells and collapsed vessels, and characterized by high pressures and negligible perfusion. The morphologies predicted here resemble biopsies (Burger and Kleihues, 1989 ) from tumoral tissue.
In Figure 3 , the dashed line labeled 'B' represents the tumor mass regression versus time. By t = 1200 the tumor undergoing chemotherapy has regressed but has stabilized at a dimensionless mass of about 471, or 89% of its value before therapy. By examining the levels of chemotherapy agent s/n v (drug molecules or nanoparticles) extravasated and diffused into the tumor in Figure 4 (a) we see that they range from near 0 to about 2.6, with much of the tumor showing levels below 1. These levels are far below that in the blood serum (s v /n v = 7). According to equations (3) and (6), this means that in a large part of the tumor the net growth rate is still positive. Even in areas where the drug concentration is adequate, the nutrient concentration n/n v is less than 1, and so the cycling fraction of cells is less than 1. This means that the regression rate is not to the fullest extent that would be expected under high nutrient conditions (e.g., in vitro). It is important to note that these results reveal that although both nutrient and drug carrier reach areas of the lesion, often the nutrient may be sufficient to keep the cells alive, whereas the drug may be insufficient to kill them. As an indication of how significantly the action of the drug is compromised by poor transport, we compute the fastest rate of regression from curve "B" in Figure 3 . From time t = 1000 corresponding to a dimensionless tumor mass of 530, to Even though levels of anticancer agent in the tumoral tissue are now approaching those in the blood serum, the tumor has split into two parts, leaving a cleft right where most of the drug is. Note that this local regression of tumoral tissue is probably exaggerated by our simulations that assume for simplicity that that tissue density is constant and equal to 1. In reality, cell death would lead to a decrease in tumoral cell density (Padera et al., 2004) around the vessels and associated to the increased delivery of drug therein.
The previous simulation has shown that because of nonuniform extravasation and diffusion, the distribution of nanoparticles in the tumoral lesion and the cells' response and regression will also be non-uniform. Anti-angiogenic therapy has been proposed to normalize tumor vasculature and overcome convection limitations by pruning and regularizing the vasculature and thus either lowering interstitial fluid pressure or the cell-cell mechanical pressure due to cell proliferation (Jain, 2001b; Padera et al., 2004) . In the first case, the lowering of interstitial pressure will increase extravasation from the blood vessels. In the second case, the lowering of mechanical stress may return collapsed tumor vessels to a functional state thus again leading to increased extravasation. To predict the best possible outcome of adjuvant anti-angiogenic therapy, we assume in the following simulation (model two) that a uniform and adequate concentration of nanoparticles has been effected at all perfused regions of the lesion independent of local pressure, and that they sit at the extravasation site releasing drug at a constant rate (see Section 2.3). This describes large, 100 nm particles that don't diffuse once extravasated. Instead, the drug molecules are released from the nanoparticles and diffuse into the tumoral tissue. Thus here we isolate the effect of diffusional limitations of drug after release from the nanoparticles. The local drug molecule concentration s is subject to the analogues to equations (1) and (2), with (1) modified into (4b) as described in Section 2.2.
The dimensionless tumor cells' mass versus time is given by the dotted-dashed line labeled 'C' in Figure 3 , with therapy beginning in this case at time t = 1100. Once again, just before therapy is begun, the situation within the tumor is as illustrated in the last frame of Figure 2 . However, in this simulation (model two) pressure is assumed to be irrelevant to extravasation. Figure 5 reveals that because of the more uniform source of drug along the vessels the number of tumor cells reached by the drug is more extensive, resulting in greater tumor mass regression. However, because of heterogeneous distribution of blood vessels, and of diffusion/uptake of the drug by the tissue, the drug distribution illustrated in Figure 5 is still far from uniform, once again leading to the stabilization of tumor mass after regression at about 65% of the mass before treatment. It is important to note however that the rate of decrease from, say, time t = 1100 to t = 1150 is still three orders of magnitude less than the rate predicted in vitro:
The tumoral lesion morphology illustrated in Figure 5 as predicted by our simulation reveals that tumor cell regression has lead to mass fragmentation in separate clusters of surviving tumor cells. This observation is in agreement with recent experimental results following antiangiogenic therapy (Kunkel et al., 2001; Lamszus et al., 2003; Bello et al., 2004) . The underlying mechanism is again nonuniform cell proliferation and death. Antiangiogenic therapy increases local levels of drug and thus of cell kill, thus leading, in the presence of weak adhesive forces, to diffusional instability characterized by separation of clusters of tumor cells that concentrate where the nutrient and drug levels are optimal for survival. Note that also in the simulation in Figure 4 (b) the onset of tumor fragmentation is evident. However, in that case no antiangiogenic therapy was performed and thus drug release is more concentrated at the center of the lesion leading only to the formation of a cleft of regressed tumor tissue therein.
In the previous simulations the neo-vasculature, once grown, was assumed to remain stationary, resulting in the phenomenon of the tumor regressing from its vasculature in regions with highest drug perfusion and thereby establishing a new mass equilibrium at significant fractions of the value of mass before therapy. While it may be true that mature vasculature is stationary, it is probably less so for immature vessels, which may advect with the tumor tissue as it regresses. We performed additional simulations where we allowed the neo-vasculature to be partially displaced by the motion of the tumoral tissue during regression (Zheng et al., 2004) . Under these conditions, most of the drug would be expected to extravasate within the tumor, possibly significantly affecting the previous results. These simulations are labeled 'D' and 'E' in Figure 3 . There is indeed a quantitative effect, with the tumor mass regressing by about 50% by time t = 1200. However, a mass equilibrium is eventually reached, and once again, a calculation shows that the rates of cell death are of the same order of magnitude as in the first two simulations and thus much smaller than in vitro.
Conclusions
We have quantitatively and graphically demonstrated the impact of fundamental transport limitations to the delivery of anticancer drug through a range of delivery modes, including nanoparticles, and to the resulting tumor response and regression. We have assumed a best-case scenario involving a single cell clone, which is drug-sensitive and does not develop resistance, no host tissue toxicity, and no specific or non-specific binding or metabolism of drug molecule carrier within the tumor. Importantly, the convective and diffusive transport limitations demonstrated apply not only to current technologies and modes of delivery, but also to very small nanoparticles currently in development capable of diffusing through the tumor interstitium and selectively targeting cancer cells.
The model used here incorporates simplifications and assumptions that must be refined in future investigations. With regard to the tumor model we make no distinction between interstitial fluid pressure and cell-cell mechanical pressure. We also assume that once cells are killed (either by apoptosis induced by therapy, or by necrosis) they immediately disappear. In reality these cells would either be encapsulated by macrophages or would lyse. Either way, their contribution to pressure within the tumor, and hence delivery of nutrients and drug, is not negligible. We are currently working on a multiphase model that distinguishes between the pressures and between multiple species of cell clones and living and dead tissue. In particular, this will enable accurate modeling of a full tumor composed of an outer vascularized region of cells in various stages of malignancy and drug resistance, encapsulating a necrotic core.
With regard to the modeling of nanoparticles and drug, we have assumed no interaction of the particles with the reticuloendothelial system and with the tumor environment, and have assumed a constant drug release without regard to nanoparticle drug loading. A direct calculation of the transfer parameters used in our model at the supercellular scale will need to come from data on drug concentration in the nanoparticles, and on release kinetics from the nanoparticles (Frieboes et al., 2004a) . Furthermore, the action of the chemotherapeutic agent has been generically described, while in reality there are as many modes and mechanisms as there are cancer cell clones and anticancer drugs. We are formulating more accurate models that take into account these phenomena.
Our simulations suggest that if "active" transport systems were used in the future by highly motile small nanoparticles, the current passive transport limitations (i.e., convection and diffusion) could in principle be overcome. For example, chemotactic transport systems for nanoparticles in response to pH gradients could be employed, mimicking the transport of immune system cells. Simulations are underway to corroborate this hypothesis.
